Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Oncogenic forms of p53 inhibit p53-regulated gene expression.

Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B.

Science. 1992 May 8;256(5058):827-30.

PMID:
1589764
2.
3.

Stimulation of polyomavirus DNA replication by wild-type p53 through the DNA-binding site.

Kanda T, Segawa K, Ohuchi N, Mori S, Ito Y.

Mol Cell Biol. 1994 Apr;14(4):2651-63.

4.
5.

Identification of regulatory regions within the KAI1 promoter: a role for binding of AP1, AP2 and p53.

Marreiros A, Czolij R, Yardley G, Crossley M, Jackson P.

Gene. 2003 Jan 2;302(1-2):155-64.

PMID:
12527206
6.

Identification of p53 gene mutations in breast cancers and their effects on transcriptional activation function.

Oh SJ, Jung JY, Shim SS, Im MY, Kim HD, Chung SY, Yoon JH.

Mol Cells. 2000 Jun 30;10(3):275-80.

7.

The tumor suppressor p53 regulates its own transcription.

Deffie A, Wu H, Reinke V, Lozano G.

Mol Cell Biol. 1993 Jun;13(6):3415-23.

8.
9.

The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53.

Zastawny RL, Salvino R, Chen J, Benchimol S, Ling V.

Oncogene. 1993 Jun;8(6):1529-35.

PMID:
8502478
10.

Novel DNA binding of p53 mutants and their role in transcriptional activation.

Zhang W, Funk WD, Wright WE, Shay JW, Deisseroth AB.

Oncogene. 1993 Sep;8(9):2555-9.

PMID:
8361764
11.

Cooperative DNA binding of p53 with TFIID (TBP): a possible mechanism for transcriptional activation.

Chen X, Farmer G, Zhu H, Prywes R, Prives C.

Genes Dev. 1993 Oct;7(10):1837-49. Erratum in: Genes Dev 1993 Dec;7(12B):2652.

12.

Overlap of the p53-responsive element and cAMP-responsive element in the enhancer of human T-cell leukemia virus type I.

Aoyama N, Nagase T, Sawazaki T, Mizuguchi G, Nakagoshi H, Fujisawa JI, Yoshida M, Ishii S.

Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5403-7.

13.
14.

Mammalian p53 can function as a transcription factor in yeast.

Schärer E, Iggo R.

Nucleic Acids Res. 1992 Apr 11;20(7):1539-45.

15.

Negative regulation of Rb expression by the p53 gene product.

Shiio Y, Yamamoto T, Yamaguchi N.

Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5206-10.

16.

Transcriptional inhibition of p53 by the MLL/MEN chimeric protein found in myeloid leukemia.

Maki K, Mitani K, Yamagata T, Kurokawa M, Kanda Y, Yazaki Y, Hirai H.

Blood. 1999 May 15;93(10):3216-24.

18.

Characterization of promoter elements involved in the down-regulation of topoisomerase IIalpha expression in a drug-resistant cell line.

Saxena D, Yiu GK, Ni X, Huang KC, Mantovani R, Jacquemin-Sablon AG, Ng SW.

Gene. 2004 Nov 10;342(1):145-55.

PMID:
15527974
20.

Use of the two-hybrid system to identify the domain of p53 involved in oligomerization.

Iwabuchi K, Li B, Bartel P, Fields S.

Oncogene. 1993 Jun;8(6):1693-6.

PMID:
8502489

Supplemental Content

Support Center